Selective Antagonists of the A2B Adenosine Receptor
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor.
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor.
leadXpro supports Creoptix at the launch event for the new waveRAPID kinetics analyzer
On December 2, 2020, leadXpro proudly celebrates its fifth anniversary and looks back on many successful projects with challenging membrane targets.
Axxam, leadXpro and MercachemSyncom Form a Strategic Alliance for Structure-based Drug Discovery Services that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.
In a partnership with Boehringer Ingelheim, leadXpro generated protein and provided the X-ray structure data to advance their drug discovery programs on CCR2, a chemokine receptor target.
Creoptix CEO Line S. Raquet and leadXpro CEO Michael Hennig look back on three years of partnership that transformed membrane protein drug discovery.
leadXpro, PSI, ETH and Sosei Heptares scientists present sensitivity improvements for XFEL measurements by using long wavelength pulses and improvements in data evaluation.
The publication provides evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism for immune evasion by tumors. Inhibition of adenosine signaling through selective small molecule inhibition of A R using AZD4635 restores T cell function
cross-presentation by CD103+ DCs resulting in antitumor immunity.
leadXpro AG announces its involvement in a multiparty research collaboration by delivering SARS-CoV-2 M-glycoprotein, a promising therapeutic target against Covid-19.
This crystallography review summarizes the current main strategies in sample delivery and their respective pros and cons, as well as some future direction.